Increased Expression of UDP-galactose Transporter Messenger RNA in Human Colon Cancer Tissues and Its Implication in Synthesis of Thomsen-Friedenreich Antigen and Sialyl Lewis A/X Determinants
Overview
Affiliations
A series of human nucleotide sugar transporters of the Golgi apparatus was recently cloned, including the transporters for UDP-galactose (UDP-Gal), UDP-N-acetylglucosamine (UDP-GlcNAc) and CMP-sialic acid (CMP-SA). We have examined the mRNA expression of these three transporters in human colon cancer tissues by reverse transcription-PCR analysis and compared it with that in nonmalignant colonic mucosa prepared from the same patients. The amount of mRNA for UDP-Gal transporter was significantly increased in colon cancer tissues compared with nonmalignant mucosa tissues (P = 0.035; n = 20). The increase was more prominent in patients with advanced colorectal cancer of Dukes' stages C and D, in which the amount of UDP-Gal transporter mRNA in cancer tissues showed on average about a 3.6-fold increase over the paired nonmalignant mucosa (statistically significant at P = 0.004; n = 14). The mRNA content of the other two transporters showed no significant difference between the paired cancer and normal tissues. When UDP-Gal transporter cDNA was stably transfected to cultured human colon cancer cells, the expression of Thomsen-Friedenreich (TF) antigen and of sialyl Lewis A (NeuAcalpha2-->3Galbeta1-->3[Fucalpha1-->4]GlcNAcbeta1-->R) and sialyl Lewis X (NeuAcalpha2-->3Galbeta1-->4[Fucalpha1-->3]GlcNAcbeta1-->R) determinants was significantly induced on transfectant cells, which resulted in markedly enhanced cell adhesion to vascular E-selectin. These findings suggest that the increase of UDP-Gal transporter mRNA is involved in the enhanced expression of cancer-associated carbohydrate determinants such as TF and sialyl Lewis A/X antigens in colon cancers.
Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.
PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.
Glycosylation: mechanisms, biological functions and clinical implications.
He M, Zhou X, Wang X Signal Transduct Target Ther. 2024; 9(1):194.
PMID: 39098853 PMC: 11298558. DOI: 10.1038/s41392-024-01886-1.
Wang D, Madunic K, Mayboroda O, Lageveen-Kammeijer G, Wuhrer M Mol Cell Proteomics. 2024; 23(6):100776.
PMID: 38670309 PMC: 11128521. DOI: 10.1016/j.mcpro.2024.100776.
Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers.
Bharadwaj R, Jaiswal S, Velarde de la Cruz E, Thakare R Diseases. 2024; 12(3).
PMID: 38534987 PMC: 10968914. DOI: 10.3390/diseases12030063.
Wang Y, Chen L, Chen J, Bai Z, Cao L Aging (Albany NY). 2023; 15(20):11554-11570.
PMID: 37889544 PMC: 10637800. DOI: 10.18632/aging.205145.